These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 30956096

  • 1. Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.
    Dionisi V, Bellarosa C, Cardano R, Rizzini EL, Ghedini P, Morganti AG, Fanti S, Monari F.
    Clin Genitourin Cancer; 2019 Jun; 17(3):e612-e617. PubMed ID: 30956096
    [No Abstract] [Full Text] [Related]

  • 2. Radium 223 dichloride for prostate cancer treatment.
    Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N.
    Drug Des Devel Ther; 2017 Jun; 11():2643-2651. PubMed ID: 28919714
    [Abstract] [Full Text] [Related]

  • 3. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S, Horton ER.
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [Abstract] [Full Text] [Related]

  • 4. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
    Vogelzang NJ.
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
    [Abstract] [Full Text] [Related]

  • 5. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
    Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, Monari F, Procopio G, Santini D, Seregni E, Valdagni R.
    Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N, Nagamori S, Wakumoto Y, Uemura H, Kimura G, Yokomizo A, Kikukawa H, Mizokami A, Kosaka T, Masumori N, Kawasaki Y, Yonese J, Nasu Y, Fukasawa S, Sugiyama T, Kinuya S, Hosono M, Yamaguchi I, Tsutsui H, Uemura H.
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E, Boni G, Galli L, Ricci S, Farnesi A, Mazzarri S, Cianci C, Mariani G, Falcone A.
    Future Oncol; 2015 Feb; 11(2):323-31. PubMed ID: 25075962
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
    Shirley M, McCormack PL.
    Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
    [Abstract] [Full Text] [Related]

  • 18. Radium Ra 223 dichloride in castration-resistant prostate cancer.
    Joung JY, Ha YS, Kim IY.
    Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.